{
  "ticker": "AGN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971713",
  "id": "02971713",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0842",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1mqm97m56my.pdf",
  "summary": "### **Appendix 4C Quarterly Report Summary (Argenica Therapeutics \u2013 AGN)**  \n\n#### **Key Operational/Financial Highlights:**  \n- **Phase 2 Trial Completion:** Final patient dosed in April 2025 for ARG-007 in acute ischemic stroke (AIS). Topline data expected **Q3 2025**. Primary endpoints focus on safety; secondary on infarct volume reduction.  \n- **Preclinical TBI Data:** Positive results in ferret model for moderate traumatic brain injury (modTBI), supporting clinical development.  \n- **Regulatory:** FDA placed **clinical hold** on US IND application for AIS (non-clinical data deemed insufficient). No impact on ongoing Australian Phase 2 trial.  \n- **Funding:**  \n  - **$1.5m non-dilutive grant** awarded (MRFF) for future stroke trials ($1m initial tranche received post-quarter).  \n  - **$10.5m cash balance** (30 June 2025) covers Phase 2 completion.  \n  - **R&D Tax Incentive** expected in Q4 2025.  \n\n#### **Cash Flow (Quarter Ended 30 June 2025):**  \n- **Net operating outflow:** **$2.36m** (R&D: $2.1m, staff: $0.4m).  \n- **Cash runway:** ~4.5 quarters at current burn rate.  \n\n---  \n**Brevity Note:** Excluded routine updates (e.g., patent grants, advisory committee formation) as non-material to immediate trading. Focused on catalysts (Phase 2 data, FDA hold), liquidity, and funding.",
  "usage": {
    "prompt_tokens": 6270,
    "completion_tokens": 343,
    "total_tokens": 6613,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:52:49.777917"
}